Cellular immune response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic malaria.

Cellular immune response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic malaria.

Publication date: Jul 24, 2024

Ghana and other parts of West Africa have experienced lower COVID-19 mortality rates than other regions. This phenomenon has been hypothesized to be associated with previous exposure to infections such as malaria. This study investigated the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the influence of previous malaria exposure. Blood samples were collected from individuals with asymptomatic or symptomatic COVID-19 (n = 217). A variety of assays were used to characterize the SARS-CoV-2-specific immune response, and malaria exposure was quantified using Plasmodium falciparum ELISA. The study found evidence of attenuated immune responses to COVID-19 among asymptomatic individuals, with elevated proportions of non-classical monocytes and greater memory B cell activation. Symptomatic patients displayed higher P. falciparum-specific T cell recall immune responses, whereas asymptomatic individuals demonstrated elevated P. falciparum antibody levels. Summarily, this study suggests that P. falciparum exposure-associated immune modulation may contribute to reduced severity of SARS-CoV-2 infection among people living in malaria-endemic regions.

Open Access PDF

Concepts Keywords
Africa asymptomatic
Classical COVID-19 West Africa
Coronavirus CP: Immunology
Epidemiology CP: Microbiology
Malaria Ghana
immune response
immunomodulation
malaria/COVID-19 interplay
P. falciparum
SARS-CoV-2
SARS-CoV-2 severity
symptomatic

Semantics

Type Source Name
disease MESH malaria
pathway KEGG Malaria
disease MESH COVID-19
disease MESH infections
disease IDO immune response
disease VO Severe acute respiratory syndrome coronavirus 2
disease IDO blood
pathway REACTOME SARS-CoV-2 Infection
disease MESH Emergency
disease MESH severe acute respiratory syndrome
disease MESH acute respiratory distress syndrome
disease MESH death
disease MESH infectious diseases
disease MESH sweating
disease VO vaccination
disease VO vaccinated
disease VO unvaccinated
disease MESH cytokine storms
disease IDO host
disease MESH inflammation
disease IDO parasite
disease IDO production
disease IDO infection
disease MESH lymphopenia
disease VO frequency
disease VO vaccine
disease IDO symptom
disease IDO assay
disease VO leukocyte
drug DRUGBANK Proline
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Estrone sulfate
disease IDO country
disease IDO pathogen
disease VO population
disease MESH chronic infection
drug DRUGBANK Coenzyme M
disease VO effective
disease MESH viral infections
disease VO report
drug DRUGBANK Etoperidone
disease MESH Pneumonia
disease MESH co infection
disease IDO history
disease IDO cell
drug DRUGBANK Fenamole
disease MESH anemia
drug DRUGBANK Tromethamine
disease VO organization
disease IDO susceptibility
disease IDO pathogen host
disease VO Plasmodium falciparum merozoite
disease VO Noora
drug DRUGBANK Efavirenz
disease MESH Long COVID
disease MESH Syndrome
drug DRUGBANK Methylergometrine
disease IDO primary infection
disease VO time
disease VO protocol
drug DRUGBANK Ethylenediamine
drug DRUGBANK Edetic Acid
drug DRUGBANK Flunarizine
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Nitrogen
disease VO storage
drug DRUGBANK Water
disease VO volume
drug DRUGBANK Streptomycin
disease VO manufacturer
disease VO Bacteria
drug DRUGBANK Glycerin
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Immune Globulin Human
disease IDO process
disease VO USA

Original Article

(Visited 3 times, 1 visits today)